GD甲状腺功能亢进中TSHR和TRAb的研究现状  

Current Research of TSHR and TRAb in Graves Disease Hyperthyroidism

作　　者：孙媛媛[1] 高冠起[2] 

机构地区：[1]泰山医学院,山东泰安271016 [2]临沂市人民医院内分泌科,山东临沂276003

出　　处：《医学综述》2012年第10期1458-1461,共4页Medical Recapitulate

基　　金：山东省自然科学基金(ZH2011HM067)

摘　　要：Graves病(GD)是常见的自身免疫性甲状腺病之一,发病机制尚不清楚。已有研究证实多个易感基因与GD发病相关,其中促甲状腺激素受体(TSHR)基因不仅是GD甲状腺功能亢进发病的一个易感基因,而且具有特异性。TSHR作为主要的自身抗原引起促甲状腺激素受体抗体(TRAb)的产生,是GD自身免疫反应的主要环节。TSHR易感基因及其编码的TSHR在免疫应答中的作用成为研究热点。由于TRAb是GD甲状腺功能亢进发生、发展的主要免疫标志,所以应关注TRAb在GD甲状腺功能亢进诊断、治疗选择、转归预测等方面的研究,为制订个体化的治疗方案提供科学依据。Graves disease （GD） is one ot the common autolmmue thyrmd diseases, the pathogenesls oi which is still unknown. Presently, several genes have been confirmed to play a major role in the pathogenesis of GD, especially the thyroid stimulating homrone receptor（TSHR） gene, which is both susceptible and spe- cific. As a major autoantigen ,TSHR is a key link in the autoimmune response of GD which can cause the pro- duction of thyrotropin receptor antibody. Because TRAb is the major immunological marker in the progress of GD, it should be paid more attention in the research in the diagnosis, therapeutic selection, and prognosis of GD, to provide scientific evidence for making individual treatment solution.

关 键 词：GRAVES病 促甲状腺激素受体 促甲状腺激素受体抗体 

分 类 号：R581.1[医药卫生—内分泌]